← Leaderboards
Grant W Cannon
University Of Utah
$1,503,248
Attributed
$1,503,248
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,503,248 · 2
By mechanism
R01$1,500,000 · 1
M01$3,248 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Utah
Same institution · by research overlap
- Jonathan Michael Dean$100,798,669
- Barry C Cole$2,637,013
- Marvin L Rallison$6,496
- William M McMahon$2,485,015
- John Haynes Weis$6,380,115
Others in their field
Top investigators on “Drug Adverse Effect”
- Elizabeth A Thom · George Washington University$121,387,653
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- John M Lachin · George Washington University$118,921,924
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,372,214
- Myron S Cohen · Family Health International$101,800,876
Research focus
Drug Adverse EffectImmunogeneticsImmunomodulatorsLaboratory RatGenetic MappingPharmacogeneticsQuantitative Trait LociGenetic MarkersGenetic ModelsGenetic SusceptibilityArthritisAnimal BreedingTetanus ToxoidAntibody TiteringBacterial ProteinsCell ProliferationClinical ResearchCollagenHuman SubjectHuman Therapy EvaluationLeukocyte Activation /TransformationRheumatoid ArthritisSkeletal Disorder ChemotherapySuperantigens
Grant awards (7)
GENETICS OF ADJUVANT-INDUCED ARTHRITIS$300,000
R01 · FY2005 · AR
GENETICS OF ADJUVANT-INDUCED ARTHRITIS$300,000
R01 · FY2004 · AR
GENETICS OF ADJUVANT-INDUCED ARTHRITIS$300,000
R01 · FY2003 · AR
GENETICS OF ADJUVANT-INDUCED ARTHRITIS$300,000
R01 · FY2002 · AR
GENETICS OF ADJUVANT-INDUCED ARTHRITIS$300,000
R01 · FY2001 · AR
ROLE OF SUPERANTIGENS IN TREATMENT OF RHEUMATOID ARTHRITIS$1,624
M01 · FY2001 · RR
ROLE OF SUPERANTIGENS IN TREATMENT OF RHEUMATOID ARTHRITIS$1,624
M01 · FY2000 · RR